Hjem › Brystkreft › Alabama
Kliniske studier for Brystkreft i Alabama
29 studier for Brystkreft søker deltakere på steder i Alabama.
Byer i Alabama
Offisiell studietekst (engelsk)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Central Alabama Research, Birmingham
RekruttererFase 3
Alder 18 til 100 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05827081A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06760819A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Alabama Oncology, Birmingham
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06369285PRE-ISPY Phase I/II Oncology Platform Program
- The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT05868226Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
- University of Alabama at Birmingham, Birmingham
RekruttererFase 2
Alder 60 og eldre · Kvinner · Oppdatert 30. sep. 2026 · NCT06105684A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Southern Cancer Center (SCC) ( Site 8000), Daphne
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07060807An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
- University of Alabama At Birmingham Hospital, Birmingham
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07222267A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Daphne
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06103864Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction
- The Kirklin Clinic, Birmingham
Rekrutterer
Alder 18 til 90 · Kvinner · Oppdatert 25. sep. 2026 · NCT06294574A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT06618287A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of Alabama at Birmingham, Birmingham
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 22. sep. 2026 · NCT07287098Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- University of Alabama at Birmingham, Birmingham
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 30 til 74 · Kvinner · Oppdatert 21. sep. 2026 · NCT02620852A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Southern Cancer Center, PC, Daphne
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT06492616Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Alabama Birmingham, Birmingham
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 10. sep. 2026 · NCT06293898Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Birmingham Hematology Associates, Birmingham
RekruttererObservasjonsstudie
Alder 18 til 99 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT07211178TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
- University of Alabama, Birmingham
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 26. aug. 2026 · NCT06533826Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Southern Cancer Center, Mobile
RekruttererFase 3
Alder 18 til 100 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT05232916Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
- University of Alabama, Birmingham, Birmingham
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 45 til 74 · Kvinner · Oppdatert 31. jul. 2026 · NCT05625659Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Uni of Alabama at Birmingham, Birmingham
RekruttererFase 1
Alder 18 til 100 · Alle kjønn · Oppdatert 29. jul. 2026 · NCT06562192Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
- The University of Alabama, Birmingham
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 15. mai 2026 · NCT06855654I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of Alabama at Birmingham, Birmingham
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 6. mai 2026 · NCT01042379Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- University of Alabama at Birmingham, Birmingham
- University of South Alabama, Mobile
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 30. apr. 2026 · NCT05297734De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- University of South Alabama Mitchell Cancer Institute, Mobile
RekruttererFase 3
Alder 50 til 70 · Alle kjønn · Oppdatert 23. apr. 2026 · NCT04852887A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- University of Alabama at Birmingham, Birmingham
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. feb. 2026 · NCT06099769Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
- The Kirklin Clinic, Birmingham
RekruttererTidlig fase 1
Alder 18 og eldre · Kvinner · Oppdatert 26. jan. 2026 · NCT03321045Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
- University of Alabama Birmingham, Birmingham
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 20. jan. 2026 · NCT05693766Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- The University of Alabama at Birmingham, Birmingham
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 16. des. 2025 · NCT04722341RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
- University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham
Rekrutterer
Alder 18 til 99 · Alle kjønn · Oppdatert 31. okt. 2025 · NCT03643861SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.